| [1] |
Meyer MA. Malignant gliomas in adults[J]. N Engl J Med, 2008, 359(17): 1850; author reply 1850.
|
| [2] |
von Neubeck C, Seidlitz A, Kitzler HH, et al. Glioblastoma multiforme: emerging treatments and stratification markers beyond new drugs[J]. Br J Radiol, 2015, 88(1053): 20150354.
|
| [3] |
Le Rhun E, Preusser M, Roth P, et al. Molecular targeted therapy of glioblastoma[J]. Cancer Treat Rev, 2019, 80: 101896.
|
| [4] |
Brown CE, Alizadeh D, Starr R, et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy[J]. N Engl J Med, 2016, 375(26): 2561-2569.
|
| [5] |
Berghoff AS, Preusser M. Does neoadjuvant anti-PD1 therapy improve glioblastoma outcome?[J]. Nat Rev Neurol, 2019, 15(6): 314-315.
|
| [6] |
Clarke JL, Iwamoto FM, Sul J, et al. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma[J]. J Clin Oncol, 2009, 27(23): 3861-3867.
|
| [7] |
Gilbert MR, Wang M, Aldape KD, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial[J]. J Clin Oncol, 2013, 31(32): 4085-4091.
|
| [8] |
Dhaouadi S, Ben Abderrazek R, Loustau T, et al. Novel human tenascin-C function-blocking camel single domain nanobodies[J]. Front Immunol, 2021, 12: 635166.
|
| [9] |
Wiemann S, Reinhard J, Faissner A. Immunomodulatory role of the extracellular matrix protein tenascin-C in neuroinflammation[J]. Biochem Soc Trans, 2019, 47(6): 1651-1660.
|
| [10] |
Midwood KS, Chiquet M, Tucker RP, et al. Tenascin-C at a glance[J]. J Cell Sci, 2016, 129(23): 4321-4327.
|
| [11] |
Angel I, Pilo Kerman O, Rousso-Noori L, et al. Tenascin C promotes cancer cell plasticity in mesenchymal glioblastoma[J]. Oncogene, 2020, 39(46): 6990-7004.
|
| [12] |
Hotchkiss KM, Sampson JH. Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor[J]. J Neurooncol, 2021, 151(1): 55-62.
|
| [13] |
Lee SY. Temozolomide resistance in glioblastoma multiforme[J]. Genes Dis, 2016, 3(3): 198-210.
|
| [14] |
Bijelic D, Adzic M, Peric M, et al. Different functions of recombinantly expressed domains of tenascin-C in glial scar formation[J]. Front Immunol, 2020, 11: 624612.
|
| [15] |
Maqbool A, Spary EJ, Manfield IW, et al. Tenascin C upregulates interleukin-6 expression in human cardiac myofibroblasts via toll-like receptor 4[J]. World J Cardiol, 2016, 8(5): 340-350.
|
| [16] |
Sonoda Y. Clinical impact of revisions to the WHO classification of diffuse gliomas and associated future problems[J]. Int J Clin Oncol, 2020, 25(6): 1004-1009.
|
| [17] |
Tang YA, Chen CH, Sun HS, et al. Global Oct4 target gene analysis reveals novel downstream PTEN and TNC genes required for drug-resistance and metastasis in lung cancer[J]. Neclei Acids Res, 2015, 43(3): 1593-1608.
|
| [18] |
Wang T, Srivastava S, Hartman M, et al. High expression of intratumoral stromal proteins is associated with chemotherapy resistance in breast cancer[J]. Oncotarget, 2016, 7(34): 55155-55168.
|
| [19] |
Nie S, Gurrea M, Zhu J, et al. Tenascn-C: a novel candidate marker for cancer stem cells in glioblatoma identified by tissue microarray[J]. J Proteome Res, 2015, 14(2): 814-822.
|